A funding round has brought in $3 million for biotech startup BioAegis Therapeutics. The company plans to file an investigational new-drug application with the FDA and launch a Phase IIb/III study of human plasma gelsolin, a natural human protein, in preventing the spread of inflammation resulting in multiple organ dysfunction syndrome in intensive care units.

Related Summaries